RecruitingNCT06591039

A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China

A Multicenter Prospective Observational Cohort Study of Breast Cancer Based on a Breast Cancer Medical Record Database in China

Sponsor

Fudan University

Enrollment

20,000 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Neoplasms

Summary

1. To construct a prospective, multi-center breast cancer treatment cohort in China, and analyze the factors affecting breast cancer diagnosis and treatment. 2. To evaluate the diagnosis and treatment and prognosis of breast cancer among patients in different regions and hospitals.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a large observational study in China building a medical records database for patients with breast cancer. By collecting data from multiple hospitals, researchers aim to better understand treatment patterns and outcomes in the Chinese population over time. **You may be eligible if...** - You have a confirmed diagnosis of a malignant breast tumor (by tissue or cell sample) — this includes early-stage breast cancer in situ, invasive breast cancer, and breast sarcoma **You may NOT be eligible if...** - There are no listed exclusion criteria for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREThe study did not involve intervention in the patient's treatment regimen

This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.